Q1 FY2026 · ended Jun 30, 2026 · Revenue $1.44M, -33.5% YoY · Filed Aug 6, 2026
Roivant Sciences Ltd. (ROIV) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q1 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.4 million and a net loss of $189.8 million. Free cash flow was -$270.9 million. As of Jun 30, 2026 it held $3.8 billion in cash and investments and $107.2 million in total debt.
Revenue
$1.44M
-33.5% vs year-ago quarter
Net income
$-189.84M
+15.0% vs year-ago quarter
Operating cash flow
$-270.50M
-32.4% vs year-ago quarter
Free cash flow
$-270.92M
-30.0% vs year-ago quarter
EPS
$-0.26
+21.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
722.32M
+5.8% vs year-ago quarter
Net cash
$3.73B
Q1 FY2026
Operating margin
-7914.8%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ROIV (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Bermuda
- Headquarters
- London
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1635088
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2026 Jun 30, 2026 |
Q4 FY2025 Mar 31, 2026 |
Q3 FY2025 Dec 31, 2025 |
Q2 FY2025 Sep 30, 2025 |
Q1 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.4M | $2.5M | $2.0M | $1.6M | $2.2M |
| Operating income | -$366.0M | $415.2M | -$339.2M | -$306.2M | -$284.9M |
| Net income | -$189.8M | $303.0M | -$265.9M | -$113.5M | -$223.4M |
| Diluted EPS | -$0.26 | $0.42 | -$0.38 | -$0.17 | -$0.33 |
| Operating cash flow | -$270.5M | -$163.8M | -$196.5M | -$185.7M | -$204.4M |
| Free cash flow | -$270.9M | -$165.1M | -$201.4M | -$193.5M | -$208.4M |
| Total assets | $5.3B | $5.7B | $5.2B | $5.1B | $5.0B |
| Total liabilities | $384.6M | $416.3M | $251.1M | $257.1M | $216.7M |
| Stockholders' equity | $4.2B | $4.5B | $4.3B | $4.4B | $4.3B |
| Cash and investments | $3.8B | $4.3B | $4.5B | $4.4B | $4.5B |
| Total debt | $107.2M | $107.4M | $108.9M | $98.8M | $99.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 18, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Other events
|
Aug 28, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 27, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 997 Roivant Sciences Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.